PRESS RELEASE published on 12/22/2025 at 15:26, 6 months 4 days ago Form 8.3 - The Vanguard Group, Inc.: Avadel Pharmaceuticals plc The Vanguard Group, Inc. discloses a 6.02% ownership in Avadel Pharmaceuticals plc. Form 8.3 submitted to the Irish Takeover Panel Form 8.3 Irish Takeover Panel The Vanguard Group Ownership Disclosure Avadel Pharmaceuticals Plc
BRIEF published on 12/22/2025 at 15:25, 6 months 4 days ago The Vanguard Group Discloses Position in International Personal Finance plc The Vanguard Group Takeover Code Securities Disclosure Shareholding International Personal Finance
BRIEF published on 12/22/2025 at 15:25, 6 months 4 days ago Le groupe Vanguard révèle sa position dans International Personal Finance plc Actionnariat Code De Prise De Contrôle Le Groupe Vanguard Information Sur Les Valeurs Mobilières Finances Personnelles Internationales
BRIEF published on 12/22/2025 at 15:25, 6 months 4 days ago The Vanguard Group Discloses Position in NCC Group plc Form 8.3 The Vanguard Group Takeover Code Securities Disclosure NCC Group Plc
BRIEF published on 12/22/2025 at 15:25, 6 months 4 days ago Le groupe Vanguard révèle sa participation dans NCC Group plc Code De Prise De Contrôle Le Groupe Vanguard Formulaire 8.3 Information Sur Les Valeurs Mobilières NCC Group Plc
PRESS RELEASE published on 12/22/2025 at 15:25, 6 months 4 days ago Form 8.3 - The Vanguard Group, Inc.: Greencore Group plc The Vanguard Group, Inc. discloses a 5.35% stake in Greencore Group plc. Additional disclosure related to Bakkavor Group plc. Transactions include purchasing 15,549 and selling 29,721 1p ordinary shares The Vanguard Group Stake Disclosure Share Transactions Greencore Group Plc Bakkavor Group Plc
BRIEF published on 12/22/2025 at 15:24, 6 months 4 days ago The Vanguard Group Discloses Position in Unite Group plc Takeover Code Securities Disclosure Vanguard Group Market Transparency Unite Group Plc
BRIEF published on 12/22/2025 at 15:24, 6 months 4 days ago Le groupe Vanguard révèle sa participation dans Unite Group plc Groupe Vanguard Code De Prise De Contrôle Transparence Du Marché Information Sur Les Valeurs Mobilières Unite Group Plc
PRESS RELEASE published on 12/22/2025 at 15:24, 6 months 4 days ago Form 8.3 - The Vanguard Group, Inc.: Bluefield Solar Income Fund Limited The Vanguard Group, Inc. discloses 1.29% stake in Bluefield Solar Income Fund Limited. Position disclosed on 19 Dec 2025. Purchase of 358,808 securities at 0.68 GBP per unit Securities Position Disclosure The Vanguard Group Inc. Purchase Bluefield Solar Income Fund Limited
PRESS RELEASE published on 12/22/2025 at 15:23, 6 months 4 days ago Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc The Vanguard Group, Inc. discloses 3.58% ownership of Spire Healthcare Group plc's 1p ordinary securities as of 19 Dec 2025 The Vanguard Group Ownership Disclosure Financial Disclosure 1p Ordinary Securities Spire Healthcare Group Plc
Published on 06/26/2026 at 14:05, 3 hours 14 minutes ago SouthGobi Announces Voting Results of Annual General Meeting of Shareholders
Published on 06/26/2026 at 14:00, 3 hours 19 minutes ago Dateline Chairman Invests $1.95 million through Options Exercise
Published on 06/26/2026 at 13:00, 4 hours 19 minutes ago Aclara Secures Tax Exemption Approval of Over US$20 Million For Its U.S. Heavy Rare Earth Separation Facility in Louisiana
Published on 06/26/2026 at 12:45, 4 hours 34 minutes ago Northern Dynasty Reports Oral Arguments Held
Published on 06/26/2026 at 17:05, 14 minutes ago NAKIKI SE Receives an Adverse Opinion on Its 2024 Financial Statements and Management Report
Published on 06/26/2026 at 17:00, 19 minutes ago Darwin AG Announces Results of the 2026 Annual General Meeting
Published on 06/26/2026 at 15:30, 1 hour 49 minutes ago JMGO Extends Special Savings Beyond Prime Day with N3 Ultimate at Its Best Price Since Launch
Published on 06/26/2026 at 15:23, 1 hour 56 minutes ago Form 8.3 - The Vanguard Group, Inc.: Tate & Lyle plc
Published on 06/26/2026 at 07:00, 10 hours 19 minutes ago Advancing Women’s Health with Rapid Diagnostics: bioMérieux files a Dual 510(k) /CLIA Waiver application to the FDA for the BIOFIRE® SPOTFIRE® Vaginitis Panel
Published on 06/26/2026 at 07:00, 10 hours 19 minutes ago Améliorer la santé des femmes grâce au diagnostic rapide : bioMérieux dépose auprès de la FDA une demande combinée d’autorisation 510(k) et de dérogation CLIA pour son test BIOFIRE® SPOTFIRE® Vaginitis Panel
